FDA panel unanimously backs Novartis' copy of Amgen's Neupogen

FDA panel unanimously backs Novartis' copy of Amgen's Neupogen

(Reuters) – A panel to the U.S. Food and Drug Administration unanimously backed the approval of Novartis AG's copy of Amgen Inc's blockbuster cancer drug Neupogen, setting the stage for the regulator's first approval of a biosimilar. The United States

9
Like
Save

Comments

Write a comment

*